Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds$33.5 ...

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance ...

The Prudential Regulation Authority said the firm’s main underwriter, UK Insurance Limited, miscalculated its balance sheet ...

GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreementExpect to complete enrollment in the CATT1 Phase 3 ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...

Learn to balance a general ledger by ensuring debits match credits, crucial for accurate financial records. Discover key steps to manage your accounts efficiently.

Meta chief says it has improved identifying underage users but adds ‘I always wish we could have gotten there sooner’ The Meta CEO, Mark Zuckerberg, testified at a landmark trial of social media ...

A Georgia father went on trial Monday, as he stands accused of enabling the 2024 high school shooting that left two students and two teachers dead by giving his teenage son access to a rifle despite ...

Opening statements are set to begin this week in the case against the father of the teen accused in a deadly 2024 school shooting in northeast Georgia. Jurors are expected to be sworn in on Monday ...